Primaa key facts
as of Oct 2026- Developer of a medical diagnostic software designed for automated and accurate histological diagnoses.
- Primaa is valued at approximately $73.9M as of Oct 2026 (last reported valuation).
- It has raised $18.0M; the latest was Later Stage VC ($8.2M) in Oct 2025.
- Notable investors include Bpifrance, Agoranov, Super Capital, Elaia Partners, 50 Partners — 14 tracked in total.
- Status: Privately Held (backing).
Primaa's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch Primaa: the Monday email on marks, rounds and moves
Primaa funding rounds
No funding rounds for Primaa are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Primaa
14+Membership and data by Private Market View
Primaa valuation
Primaa's last reported valuation was $73.9 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
Primaa investors
14 investors are on record for Primaa, including Bpifrance, Agoranov, Super Capital and Elaia Partners.
About Primaa
Developer of a medical diagnostic software designed for automated and accurate histological diagnoses. The company's software is an artificial intelligence-based tool that facilitates cancer detection by digitizing the slides and collecting images in a database, enabling clients to digitally identify tissue damage and perform an increasing number of diagnoses while maintaining an unwavering level of reliability.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2018
- Employees
- 25
- Website
- primaalab.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.